Skip to main content
OpenTrials
Completed

NCT Number: NCT02275780

Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018)

To establish a new treatment option for treatment-naïve participants with HIV-1, the efficacy and safety of doravirine will be determined relative to a protease inhibitor (PI). Participants will receive double-blind treatment during the 96-week Base Study. Eligible participants in either of the Base Study groups will continue to receive the doravirine-containing regimen open label for an additional 96 weeks in the Study Extension 1. Eligible participants who are deriving benefit will continue in Study Extension 2 to receive the doravirine-containing regimen open label until doravirine becomes locally available or for an additional 96 weeks, whichever comes first. The primary hypothesis is that doravirine 100 mg once a day (q.d.) is non-inferior to darunavir/ritonavir (800 mg/100 mg) q.d., each in combination with TRUVADA™ or EPZICOM™/KIVEXA™, as assessed by the proportion of participants with HIV-1 ribonucleic acid (RNA) <50 copies/mL at Week 48. If non-inferiority is established, then the superiority of doravirine 100 mg q.d. compared to darunavir/ ritonavir (800 mg/100 mg) q.d. will be assessed.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

HIV-1

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

About this study

Participants in Australia, Russia, and South Africa who are deriving benefit from MK-1439A are also eligible to continue receiving study drug during Study Extension 3, which will last for 2 years or until drug is available locally, whichever comes first.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Is HIV-1 positive and has HIV treatment indicated based on physician assessment.
  • Has received no (0 days of) antiretroviral therapy (ART), including investigational antiretroviral agents.
  • Is considered clinically stable with no signs or symptoms of active infection for at least 2 weeks prior to the start of treatment.
  • Female is highly unlikely to become pregnant, or male is highly unlikely to impregnate a partner because they are not of reproductive potential, or agree to practice abstinence or use acceptable contraception for up to 14 days after the last dose of study drug.
  • Eligibility for the Study Extension 1 at the Week 96 visit: 1) completed the Week 96 visit, 2) derived benefit from participation through Week 96 in the opinion of the investigator, 3) is a clinically-appropriate candidate for an additional 96 weeks of treatment with the Study Extension regimen.
  • Eligibility for the Study Extension 2 at the Week 192 visit: 1) completed the Week 192 visit, 2) derived benefit from participation through Week 192 in the opinion of the investigator, 3) is a clinically-appropriate candidate for 96 weeks of treatment with the Study Extension regimen.

Exclusion criteria

  • Uses or has had a recent history of using recreational or illicit drugs.
  • Has been treated for a viral infection other than HIV-1, such as hepatitis B, with an agent that is active against HIV-1.
  • Has documented or known resistance to study drugs including doravirine, darunavir, ritonavir, emtricitabine, tenofovir, abacavir and/or lamivudine.
  • Has participated in a study with an investigational compound/device within the prior month, or anticipates doing so during this study.
  • Has used systemic immunosuppressive therapy or immune modulators within the prior 30 days, or anticipates doing so during this study.
  • Has significant hypersensitivity or other contraindication to any of the components of the study drugs.
  • Has a current (active) diagnosis of acute hepatitis due to any cause.
  • Is pregnant, breastfeeding or expecting to conceive at any time during the study.
  • Female who expects to donate eggs, or male who expects to donate sperm at any time during the study.

Treatment and study plan

Doravirine

Drug

Doravirine 100 mg tablet administered p.o. q.d.

Darunavir

Drug

Darunavir 800 mg tablet administered p.o. q.d.

Ritonavir

Drug

Ritonavir 100 mg tablet administered p.o. q.d.

TRUVADA™ or EPZICOM™/KIVEXA™

Drug

The investigator selects either TRUVADA™, a tablet containing 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate p.o. q.d. or EPZICOM™/KIVEXA™, a tablet containing 600 mg abacavir sulfate and 300 mg lamivudine, p.o. q.d.

Primary outcomes

  1. Percentage of Participants Achieving Plasma HIV-1 RNA <50 Copies/mL at Week 48

    Time frame: Week 48

    The percentage of participants in each arm achieving HIV-1 RNA levels <50 copies/mL at Week 48 was determined. Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled according to the US Food and Drug Administration (FDA) "snapshot" approach and all missing data were considered treatment failures, regardless of the reason.

Secondary outcomes

  1. Percentage of Participants Achieving Plasma HIV-1 RNA <50 Copies/mL at Week 96

    Time frame: Week 96

    The percentage of participants in each arm achieving HIV-1 RNA levels <50 copies/mL at Week 96 was determined. Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled according to the US Food and Drug Administration (FDA) "snapshot" approach and all missing data were considered treatment failures, regardless of the reason.

  2. Change From Baseline in Mean CD4+ T-cell Count at Week 48

    Time frame: Baseline and Week 48

    CD4+ T-cell counts were quantified by a central laboratory using a commercially available assay.

  3. Change From Baseline in Mean CD4+ T-cell Count at Week 96

    Time frame: Baseline and Week 96

    CD4+ T-cell counts were quantified by a central laboratory using a commercially available assay.

  4. Mean Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 48

    Time frame: Baseline and Week 48

    Serum LDL-C was determined after an overnight fast. Change from Baseline was analyzed using ANCOVA models with terms for Baseline lipid level and treatment group. The Last Observation Carry Forward (LOCF) approach was applied for missing data or data collected after modifying lipid-lowering therapy.

  5. Mean Change From Baseline in Fasting Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 48

    Time frame: Baseline and Week 48

    Serum non-HDL-C was determined after an overnight fast. Change from Baseline was analyzed using ANCOVA models with terms for Baseline lipid level and treatment group. The LOCF approach was applied for missing data or data collected after modifying lipid-lowering therapy.

  6. Mean Change From Baseline in Fasting High Density Lipoprotein Cholesterol (HDL-C) at Week 48

    Time frame: Baseline and Week 48

    Serum HDL-C was determined after an overnight fast. Change from Baseline was analyzed using ANCOVA models with terms for Baseline lipid level and treatment group. The LOCF approach was applied for missing data or data collected after modifying lipid-lowering therapy.

  7. Mean Change From Baseline in Fasting Total Cholesterol at Week 48

    Time frame: Baseline and Week 48

    Serum total cholesterol was determined after an overnight fast. Change from Baseline was analyzed using ANCOVA models with terms for Baseline lipid level and treatment group. The LOCF approach was applied for missing data or data collected after modifying lipid-lowering therapy.

  8. Mean Change From Baseline in Fasting Triglyceride at Week 48

    Time frame: Baseline and Week 48

    Serum triglyceride was determined after an overnight fast. Change from Baseline was analyzed using ANCOVA models with terms for Baseline lipid level and treatment group. The LOCF approach was applied for missing data or data collected after modifying lipid-lowering therapy.

  9. Percentage of Participants With Any Adverse Event

    Time frame: Up to 98 weeks

    An adverse event (AE) is defined as any untoward medical occurrence in a study participant and which does not necessarily have to have a causal relationship to treatment. An adverse event can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the study treatment or protocol-specified procedure, whether or not considered related to study treatment or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the study treatment is also an AE. The percentage of participants with any AE was assessed.

  10. Percentage of Participants With Any Serious Adverse Event

    Time frame: Up to 98 weeks

    A serious adverse event is an AE that results in death, is life threatening, results in persistent or significant disability or incapacity, results in or prolongs a hospitalization, is a congenital anomaly or birth defect, is a cancer, is associated with an overdose, or is another important medical event. The percentage of participants with any SAE was assessed.

  11. Percentage of Participants With Any Drug-related Adverse Event

    Time frame: Up to 98 weeks

    The investigator was to determine if an AE had a reasonable possibility of a relationship to the study drug. The percentage of participants with any drug-related AE was assessed.

  12. Percentage of Participants With Any Drug-related Serious Adverse Event

    Time frame: Up to 98 weeks

    The percentage of participants with any drug-related SAE was assessed.

  13. Percentage of Participants Who Discontinued Study Treatment Due to an Adverse Event

    Time frame: Up to 96 weeks

    The percentage of participants who discontinued study treatment due to an AE was assessed.

  14. Percentage of Participants Achieving Plasma HIV-1 RNA <40 Copies/mL at Week 48

    Time frame: Week 48

    The percentage of participants in each arm achieving HIV-1 RNA levels <40 copies/mL at Week 48 was determined. Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled according to the US Food and Drug Administration (FDA) "snapshot" approach and all missing data were considered treatment failures, regardless of the reason.

  15. Percentage of Participants Achieving Plasma HIV-1 RNA <40 Copies/mL at Week 96

    Time frame: Week 96

    The percentage of participants in each arm achieving HIV-1 RNA levels <40 copies/mL at Week 96 was determined. Plasma HIV-1 RNA levels were quantified with the Abbott RealTime HIV-1 Assay. Data were handled according to the US Food and Drug Administration (FDA) "snapshot" approach and all missing data were considered treatment failures, regardless of the reason.

Sponsors and collaborators

Lead sponsor

Merck Sharp & Dohme LLC

Industry

Registry information

Official study title

A Phase 3 Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Doravirine (MK-1439) 100 mg Once Daily Versus Darunavir 800 mg Once Daily Plus Ritonavir 100 mg Once Daily, Each in Combination With TRUVADA™ or EPZICOM™/KIVEXA™, in Treatment-Naïve HIV-1 Infected Subjects

Acronym: DRIVE-FORWARD

Important dates

Study start
2014
Primary completion
2016
Study completion
2023
First posted
Oct 27, 2014
Registry last updated
Oct 1, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.